Lisdexamfetamine (Vyvanse) Withdrawal in Children with Orofacial Cleft and Attention-Deficit/Hyperactivity Disorder

      Stimulants are the first line of therapy for attention-deficit/hyperactivity disorder (ADHD) in children 6 years and older. Vyvanse is a long acting prodrug stimulant with well-established safety, tolerability and efficacy, when compared to other stimulants such as amphetamine and methylphenidate, and non-stimulants such as atomoxetine, guanfacine, and clonidine. Treatment related adverse events for stimulant drugs in all age groups have been reported in great detail, but there is limited data available in the literature regarding withdrawal symptoms from acute cessation or dose reduction in children.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to British Journal of Oral and Maxillofacial Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect